新辅助化疗序贯同步放化疗对比单纯同步放化疗治疗局部晚期鼻咽癌:III期多中心随机对照试验
该III期多中心随机对照试验纳入476例III-IVB期(除外T3N0-1)鼻咽癌患者,随机分为新辅助化疗序贯同步放化疗组(238例)与单纯同步放化疗组(238例)。新辅助化疗组3年无病生存率高于对照组(82.0% vs 74.1%,P=0.028),3年无远处转移生存率组间差异接近统计学显著(86.0% vs 82.0%,P=0.056),总生存无显著差异。
要点
- 新辅助化疗序贯同步放化疗较单纯同步放化疗提高3年无病生存率(82.0% vs 74.1%,P=0.028)。
- 3年无远处转移生存率组间差异接近统计学显著(86.0% vs 82.0%,P=0.056)。
- 总生存与无局部区域复发生存率组间无统计学显著差异。
核心结论
- 在局部晚期鼻咽癌中,新辅助化疗较单纯同步放化疗改善了肿瘤控制,尤其在远处转移方面,但总生存未见早期获益,需要更长时间随访以确定最终疗效。
研究设计与样本
- III期多中心随机对照试验,纳入III-IVB期(除外T3N0-1)鼻咽癌患者476例,随机分为新辅助化疗序贯同步放化疗组(n=238)与单纯同步放化疗组(n=238)。
- 两组均接受顺铂80 mg/m2每3周同步放疗;新辅助化疗组在同步放化疗前接受顺铂(80 mg/m2 d1)联合氟尿嘧啶(800 mg/m2 civ d1-5)每3周共2周期。
- 主要终点为无病生存期与无远处转移生存期,次要终点为总生存;采用Kaplan-Meier法及log-rank检验分析生存曲线,P值基于5年终点计算。
主要发现
- 新辅助化疗组3年无病生存率高于对照组(82.0%,95%CI 0.77-0.87 vs 74.1%,95%CI 0.68-0.80,P=0.028)。
- 新辅助化疗组3年无远处转移生存率为86.0%,对照组为82.0%,差异接近统计学显著(P=0.056)。
- 两组总生存率无统计学显著差异(新辅助化疗组88.2% vs 对照组88.5%,P=0.815)。
- 两组无局部区域复发生存率无统计学显著差异(新辅助化疗组94.3% vs 对照组90.8%,P=0.430)。
- 新辅助化疗期间最常见3-4级毒性为中性粒细胞减少(16.0%);同步放化疗期间新辅助化疗组3-4级毒性显著更多(P<0.001)。
关键数值与推荐
- 新辅助化疗方案:顺铂80 mg/m2 d1联合氟尿嘧啶800 mg/m2 civ d1-5,每3周共2周期。
- 同步放化疗方案:顺铂80 mg/m2每3周同步放疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 总生存未见早期获益。
- 需要更长时间随访以确定最终疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of neoadjuvant chemotherapy (NACT) for locoregionally advanced nasopharyngeal carcinoma (NPC) is unclear. We aimed to evaluate the feasibility and efficacy of NACT followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced NPC. METHODS: Patients with stage III-IVB (excluding T3N0-1) NPC were randomly assigned to receive NACT followed by CCRT (investigational arm) or CCRT alone (control arm). Both arms were treated with 80 mg/m2 cisplatin every 3 weeks concurrently with radiotherapy. The investigational arm received cisplatin (80 mg/m2 d1) and fluorouracil (800 mg/m2 civ d1-5) every 3 weeks for two cycles before CCRT. The primary end-point was disease-free survival (DFS) and distant metastasis-free survival (DMFS). Secondary end-point was overall survival (OS). Survival curves for the time-to-event endpoints were analyzed by the Kaplan-Meier method and compared using the log-rank test. The P value was calculated using the 5-year endpoints. RESULTS: Four hundred seventy six patients were randomly assigned to the investigational (n = 238) and control arms (n = 238). The investigational arm achieved higher 3-year DFS rate (82.0%, 95% CI = 0.77-0.87) than the control arm (74.1%, 95% CI = 0.68-0.80, P = 0.028). The 3-year DMFS rate was 86.0% for the investigational arm versus 82.0% for the control arm, with marginal statistical significance (P = 0.056). However, there were no statistically significant differences in OS or locoregional relapse-free survival (LRRFS) rates between two arms (OS: 88.2% versus 88.5%, P = 0.815; LRRFS: 94.3% versus 90.8%, P = 0.430). The most common grade 3-4 toxicity during NACT was neutropenia (16.0%). During CCRT, the investigational arm experienced statistically significantly more grade 3-4 toxicities (P < 0.001). CONCLUSION: NACT improved tumour control compared with CCRT alone in locoregionally advanced NPC, particularly at distant sites. However, there was no early gain in OS. Longer follow-up is needed to determine the eventual therapeutic efficacy.
引用
- Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer. 2017. PMID: 28214653. doi:10.1016/j.ejca.2016.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。